The company says SENTI-202 is an investigational cell therapy for treating relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML). The ongoing Phase 1 trial aims to provide initial efficacy data by the end of 2024 and durability data in 2025.

Timothy Lu, CEO and Co-Founder of Senti Bio, expressed gratitude for CIRM’s support, highlighting SENTI-202’s potential to improve AML treatment. The trial, enrolling adult patients with specific hematologic malignancies in the US and Australia, evaluates two dose levels of SENTI-202 cells administered in cycles after disease-specific conditioning.

Read Also: What’s Going On With GameStop Stock Monday?

Is SNTI A Good Stock To Buy?

An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages – like Senti Biosciences‘s page for example – there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter.

For example, if you're looking to earn an annualized return of 14.97%, you'll need to buy a share of Global Net Lease by the Jul. 11, 2024. Once done, you can expect to receive a nominal payout of $0.28 on Jul. 16, 2024.

According to data from Benzinga Pro, SNTI has a 52-week high of $1.09 and a 52-week low of $0.21.